Skip to main content
NVCR
NASDAQ Life Sciences

NovoCure 第一季度净亏损翻倍至 7100 万美元，EPS 为（0.62 美元），尽管收入增加 12%

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$12.34
Mkt Cap
$1.358B
52W Low
$9.82
52W High
$20.06
Market data snapshot near publication time

summarizeSummary

NovoCure Ltd 公布了 2026 年第一季度的业绩报告，显示公司盈利能力明显恶化，净亏损增加一倍以上，达到 7114 万美元，摊薄后每股亏损扩大至（0.62 美元），较去年同期的（0.31 美元）有所增加。这一结果出现在收入增加 12.3% 至 1.7406 亿美元的背景下，收入增长得益于国际患者数量的增长和产品扩张，包括 Optune Pax 在美国的发布。虽然公司也强调了第三期 METIS 和第二期 PANOVA-4 临床试验的积极结果，但亏损的大幅增加是一个重大负面因素，可能会掩盖收入增长和临床动力，对投资者来说是一个负面消息。交易者将关注公司是否改善成本管理以及未来收入增长是否能够弥补这些扩大的亏损。

在该公告发布时，NVCR的交易价格为$12.34，交易所为NASDAQ，所属行业为Life Sciences，市值约为$13.6亿。 52周交易区间为$9.82至$20.06。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed NVCR - Latest Insights

NVCR
Apr 30, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
NovoCure Q1 Net Loss Doubles to $71M, EPS ($0.62), Despite 12% Revenue Jump
Sentiment: Negative
View Wiseek Article
NVCR
Apr 30, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
NovoCure Raises Full-Year Guidance and Reports Strong Q1 Revenue Growth Despite Non-Cash Loss
Sentiment: Positive
View Wiseek Article
NVCR
Apr 30, 2026, 7:01 AM EDT
Filing Type: 10-Q
Importance Score:
7
NovoCure Reports Widened Q1 Net Loss Driven by One-Time Expense, Highlights Positive Clinical Trial Data & FDA Approval
Sentiment: Neutral
View Wiseek Article
NVCR
Apr 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
NovoCure Seeks Shareholder Approval for Expanded Equity Incentive Plan, Proposing 9 Million Additional Shares
Sentiment: Neutral
View Wiseek Article
NVCR
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
NovoCure Reports Positive Phase 2 Trial Results for Pancreatic Cancer Therapy
Sentiment: Positive
View Wiseek Article
NVCR
Mar 02, 2026, 8:02 AM EST
Source: dpa-AFX
Importance Score:
8
NovoCure's Optune Lua Secures Key Reimbursement in Japan for NSCLC Patients
Sentiment: Positive
View Wiseek Article
NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
NovoCure Secures FDA Approval for Optune Pax in Pancreatic Cancer Amidst Mixed FY25 Financials and Clinical Setbacks
Sentiment: Neutral
View Wiseek Article
NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
NovoCure Reports Q4/FY25 Results, Guides Towards 2026 Profitability Amidst CMO Resignation
Sentiment: Positive
View Wiseek Article
NVCR
Feb 24, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
CMS Reinstates NovoCure's Billing Privileges Retroactively, Reversing Prior Revocation
Sentiment: Positive
View Wiseek Article
NVCR
Feb 11, 2026, 5:24 PM EST
Filing Type: 8-K
Importance Score:
9
NovoCure Receives FDA Approval for Optune Pax in Locally Advanced Pancreatic Cancer
Sentiment: Positive
View Wiseek Article